InvestSMART

LTR Pharma Ltd (ASX: LTP) - Announcements

- Current share price for LTP : $0.490

ASX company news and announcements for LTR Pharma Ltd (LTP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All LTR Pharma Ltd (LTP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than LTR Pharma Ltd (LTP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for LTR Pharma Ltd (LTP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$89 US ED Specialist Dr Sun Joins LTR Advisory Board 18 Aug 2025 8:41AM $0.355 $0.490 risen by 38.03%
$89 US ED Specialist Dr Pearlman Joins LTR Advisory Board 11 Aug 2025 8:39AM $0.325 $0.490 risen by 50.77%
$89 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jul 2025 8:41AM $0.370 $0.490 risen by 32.43%
$89 Proposed issue of securities - LTP 29 Jul 2025 8:36AM $0.370 $0.490 risen by 32.43%
$89 Notification regarding unquoted securities - LTP 14 Jul 2025 8:40AM $0.285 $0.490 risen by 71.93%
$89 LTP Completes Extractables Study Milestone for SPONTAN 30 Jun 2025 8:32AM $0.300 $0.490 risen by 63.33%
$89 Urological Expert Appointed to LTR Scientific Advisory Board 21 May 2025 8:22AM $0.390 $0.490 risen by 25.64%
$89 SPONTAN Expands Patient Access via National Pharmacy Network 20 May 2025 8:27AM $0.280 $0.490 risen by 75%
$89 LTR Signs Collaborative Agreement to Develop OMD Nasal Spray 8 May 2025 8:35AM $0.385 $0.490 risen by 27.27%
$89 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2025 9:15AM $0.390 $0.490 risen by 25.64%
$89 Change of Registered Office Address 4 Apr 2025 6:05PM $0.365 $0.490 risen by 34.25%
$89 Change of Company Secretary 1 Apr 2025 9:49AM $0.460 $0.490 risen by 6.52%
$89 Investor Presentation 27 Mar 2025 10:27AM $0.450 $0.490 risen by 8.89%
$89 Commercial Update and Regulatory Progress 26 Mar 2025 8:58AM $0.480 $0.490 risen by 2.08%
$89 LTR Pharma to Showcase SPONTAN Data at Urology Conference 28 Feb 2025 8:40AM $0.625 $0.490 fallen by 21.60%
$89 Appendix 4D and Half Yearly Report 27 Feb 2025 8:31AM $0.615 $0.490 fallen by 20.33%
$89 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2025 8:34AM $0.790 $0.490 fallen by 37.97%
$89 LTR Signs Symbion National Pharmacy Distribution Agreement 22 Jan 2025 8:40AM $0.700 $0.490 fallen by 30%
$89 Response to ASX Query Letters 30 Dec 2024 4:11PM $0.825 $0.490 fallen by 40.61%
$89 Agreement with Men's Health Pharmacy for SPONTAN access 19 Dec 2024 8:20AM $0.840 $0.490 fallen by 41.67%
$89 Cleansing Notice 17 Dec 2024 8:38AM $0.860 $0.490 fallen by 43.02%
$89 Application for quotation of securities - LTP 17 Dec 2024 8:37AM $0.860 $0.490 fallen by 43.02%
$89 Early Launch of Online Mens Health Platform 12 Dec 2024 8:28AM $0.930 $0.490 fallen by 47.31%
$89 Change of Company Secretary 11 Dec 2024 3:55PM $0.940 $0.490 fallen by 47.87%
$89 Investor Presentation 10 Dec 2024 9:08AM $1.050 $0.490 fallen by 53.33%

51 - 75 of 138 results

Page 3 of 6

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.